MX2023002539A - Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv). - Google Patents
Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv).Info
- Publication number
- MX2023002539A MX2023002539A MX2023002539A MX2023002539A MX2023002539A MX 2023002539 A MX2023002539 A MX 2023002539A MX 2023002539 A MX2023002539 A MX 2023002539A MX 2023002539 A MX2023002539 A MX 2023002539A MX 2023002539 A MX2023002539 A MX 2023002539A
- Authority
- MX
- Mexico
- Prior art keywords
- conditions
- mediated diseases
- methods
- pde
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063076774P | 2020-09-10 | 2020-09-10 | |
| PCT/US2021/049870 WO2022056265A1 (en) | 2020-09-10 | 2021-09-10 | Methods of treating pde iv-mediated diseases or conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002539A true MX2023002539A (es) | 2023-03-14 |
Family
ID=78080507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002539A MX2023002539A (es) | 2020-09-10 | 2021-09-10 | Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv). |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12622915B2 (enExample) |
| EP (1) | EP4210674A1 (enExample) |
| JP (2) | JP7826294B2 (enExample) |
| KR (1) | KR20230066350A (enExample) |
| CN (1) | CN116507336B (enExample) |
| AU (1) | AU2021338837A1 (enExample) |
| BR (1) | BR112023004214A2 (enExample) |
| CA (1) | CA3191177A1 (enExample) |
| CL (1) | CL2023000648A1 (enExample) |
| IL (1) | IL300628A (enExample) |
| MX (1) | MX2023002539A (enExample) |
| WO (1) | WO2022056265A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2025224045A1 (en) * | 2024-02-22 | 2026-08-06 | Vanda Pharmaceuticals, Inc. | Treatment of dry eye disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0314392A (pt) | 2002-09-16 | 2005-07-12 | Glaxo Group Ltd | Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação |
| PL378245A1 (pl) | 2003-01-09 | 2006-03-20 | Astellas Pharma Inc. | Pochodne pirolopirydazyny |
| WO2007142929A2 (en) | 2006-05-31 | 2007-12-13 | The University Of North Carolina At Chapel Hill | Novel pde4 inhibitors |
| US8080563B2 (en) * | 2006-07-07 | 2011-12-20 | Kalypsys | Bicyclic heteroaryl inhibitors of PDE4 |
| ES2909316T3 (es) | 2015-12-24 | 2022-05-06 | Univ California | Reguladores de CFTR y métodos de uso de los mismos |
| KR20200044873A (ko) | 2017-08-24 | 2020-04-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 안구 제약학적 조성물 |
| TWI845795B (zh) * | 2019-12-05 | 2024-06-21 | 美商汎達製藥公司 | 眼用醫藥組合物 |
-
2021
- 2021-09-10 CN CN202180062221.XA patent/CN116507336B/zh active Active
- 2021-09-10 EP EP21787173.0A patent/EP4210674A1/en active Pending
- 2021-09-10 WO PCT/US2021/049870 patent/WO2022056265A1/en not_active Ceased
- 2021-09-10 JP JP2023515808A patent/JP7826294B2/ja active Active
- 2021-09-10 IL IL300628A patent/IL300628A/en unknown
- 2021-09-10 KR KR1020237008089A patent/KR20230066350A/ko active Pending
- 2021-09-10 BR BR112023004214A patent/BR112023004214A2/pt unknown
- 2021-09-10 CA CA3191177A patent/CA3191177A1/en active Pending
- 2021-09-10 US US18/044,805 patent/US12622915B2/en active Active
- 2021-09-10 AU AU2021338837A patent/AU2021338837A1/en active Pending
- 2021-09-10 MX MX2023002539A patent/MX2023002539A/es unknown
-
2023
- 2023-03-07 CL CL2023000648A patent/CL2023000648A1/es unknown
-
2026
- 2026-02-25 JP JP2026028686A patent/JP2026102632A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021338837A1 (en) | 2023-04-06 |
| WO2022056265A1 (en) | 2022-03-17 |
| JP2023541261A (ja) | 2023-09-29 |
| JP7826294B2 (ja) | 2026-03-09 |
| BR112023004214A2 (pt) | 2023-04-11 |
| CA3191177A1 (en) | 2022-03-17 |
| IL300628A (en) | 2023-04-01 |
| US20230364100A1 (en) | 2023-11-16 |
| KR20230066350A (ko) | 2023-05-15 |
| CN116507336A (zh) | 2023-07-28 |
| EP4210674A1 (en) | 2023-07-19 |
| CL2023000648A1 (es) | 2023-10-13 |
| JP2026102632A (ja) | 2026-06-23 |
| US12622915B2 (en) | 2026-05-12 |
| CN116507336B (zh) | 2026-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20240147A (es) | Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| SA522432955B1 (ar) | Kras g12c مثبطات | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| GEAP202315746A (en) | Protein tyrosine phosphatase inhibitors | |
| MX2022010795A (es) | Hidrato cristalino de un compuesto inhibidor de jak. | |
| MY200810A (en) | Pyrrolidine compounds | |
| MX2024000299A (es) | Compuestos antivirales. | |
| MX2025008327A (es) | Composiciones y metodos para el tratamiento de trastornos del snc | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| EP4365179A3 (en) | Novel rapamycin derivatives | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| PH12022550491A1 (en) | Perk inhibiting pyrrolopyrimidine compounds | |
| PH12022550497A1 (en) | Perk inhibiting compounds | |
| MX2024003952A (es) | Combinación que comprende atogepant para tratar la migraña. | |
| MX2025001982A (es) | Inhibidores de kif18a y usos de estos | |
| ZA202300912B (en) | Tyk-2 inhibitor | |
| NZ754944A (en) | Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors | |
| MX394860B (es) | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| MX2024006684A (es) | Inhibidores de hdac novedosos y uso terapéutico de estos. |